COMP <GO>
MDLN vs BSX // EV/EBITDA & P/E VALUATION
Medline Inc. (NASDAQ) VS. Boston Scientific Corporation (NYSE) • 15-METRIC TALLY: MDLN 2
— BSX 9
▲ EV/EBITDA & P/E VALUATION LEADER: BSX
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
valuation
20.3x
LAST: $41.98 (-1.66%) • MKT CAP: $61.87B
valuation
15.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. BSX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | BSX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 69.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 9.20% | -1.00 | BSX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.3x | 15.8x | +4.50 | BSX | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 5.91% | -2.83 | BSX | /fcf-yield <GO> |
| Operating Margin | 7.80% | 18.00% | -10.20 | BSX | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 14.00% | +54.00 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 19.90% | -8.40 | BSX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 2.77 | -0.27 | BSX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | BSX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 43.0 | -12.10 | BSX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.99 | +0.12 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $61.87B | -$19.80B | BSX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | BSX REV | MDLN GROSS % | BSX GROSS % | MDLN FCF | BSX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $20.07B | 26.4% | 69.0% | $1.30B | $3.66B |
| FY 2024 | $25.51B | $16.75B | 27.3% | 68.6% | $1.42B | $2.65B |
| FY 2023 | $23.23B | $14.24B | — | — | $639.6M | $1.86B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
BSX // BETA 0.99